Benzinga

Benzinga

Benzinga

domingo, agosto 30

Cogent Biosciences Inc

COGTNASDAQ
Trade with Public
Trade with Public
$34.67
-2.42-6.52%
al cierre: Aug 28, 5:00 PM EST
$34.59
-0.0839-0.24%
After hour: Aug 28, 5:00 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Cogent Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cogent Biosciences (COGT).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

1S.Buy
8Buy
3Hold
Consensus RatingBuy# Analysts12Avg. Consensus PT$38Upside to Avg. PT+8.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026Piper SandlerChristopher RaymondPT RaiseOverweight$52→$55
Aug 12, 2026GuggenheimMichael SchmidtPT RaiseBuy$45→$52
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55

HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $52 to $55.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $52

Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $39 to $52.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved